Literature DB >> 1910867

Hepoxilin A3 increases vascular permeability in the rat skin.

O Laneuville1, E J Corey, R Couture, C R Pace-Asciak.   

Abstract

We have recently shown that hepoxilins are formed by and act on human neutrophils leading to an increase in intracellular levels of calcium and activation of the release of arachidonic acid and diacylglycerol [6, 9]. Since neutrophil activation and accumulation is involved in the inflammatory process resulting in vascular permeability in the rat skin, we investigated the effects of hepoxilins on this process. Hepoxilins administered s.c. resulted in a concentration- and time-dependent leakage of dye to the extravascular compartment of skin from rats to which Evans Blue had been administered. These results were compared to experiments in which prostaglandin E2 was used. The threshold dose of hepoxilin that elicited an effect reached a level of significance over control within 5 min of administration at the 10 ng dose (139% +/- 7%, n = 6). Similar findings were obtained with prostaglandin E2, the level of significance was reached also at 5 min at the 10 ng dose (177% +/- 7% of control, n = 6). The maximum effect observed for both hepoxilin and prostaglandin E2 was 60 min although this did not differ significantly from 30 min except for the highest dose of PGE2 (100 ng). However, the extent of the effect observed for prostaglandin E2 was greater than that for hepoxilin after longer periods, i.e. at 60 min, the prostaglandin E2 effect being 238% +/- 10% of control, and hepoxilin A3 being 167% +/- 10% of control. These results demonstrate that hepoxilins may participate in inflammatory processes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910867

Source DB:  PubMed          Journal:  Eicosanoids        ISSN: 0934-9820


  11 in total

Review 1.  The hepoxilins and some analogues: a review of their biology.

Authors:  Cecil R Pace-Asciak
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

2.  Biosynthesis of 14,15-hepoxilins in human l1236 Hodgkin lymphoma cells and eosinophils.

Authors:  Asa Brunnström; Mats Hamberg; William J Griffiths; Bengt Mannervik; Hans-Erik Claesson
Journal:  Lipids       Date:  2010-10-29       Impact factor: 1.880

Review 3.  Hepoxilins: a review on their enzymatic formation, metabolism and chemical synthesis.

Authors:  C R Pace-Asciak; D Reynaud; P M Demin
Journal:  Lipids       Date:  1995-02       Impact factor: 1.880

4.  Hepoxilins sensitize blood vessels to noradrenaline--stereospecificity of action.

Authors:  O Laneuville; R Couture; C R Pace-Asciak
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

5.  Mammalian soluble epoxide hydrolase is identical to liver hepoxilin hydrolase.

Authors:  Annette Cronin; Martina Decker; Michael Arand
Journal:  J Lipid Res       Date:  2011-01-07       Impact factor: 5.922

6.  Neurokinin A-induced contraction of guinea-pig isolated trachea: potentiation by hepoxilins.

Authors:  O Laneuville; R Couture; C R Pace-Asciak
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

7.  Hepoxilin A3 is the endogenous lipid mediator opposing hypotonic swelling of intact human platelets.

Authors:  A Margalit; Y Sofer; S Grossman; D Reynaud; C R Pace-Asciak; A A Livne
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

8.  Hepoxilin A3-specific binding in human neutrophils.

Authors:  D Reynaud; P Demin; C R Pace-Asciak
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

Review 9.  The role of neutrophils in the event of intestinal inflammation.

Authors:  Karen L Mumy; Beth A McCormick
Journal:  Curr Opin Pharmacol       Date:  2009-10-24       Impact factor: 5.547

10.  Distinct isoforms of phospholipase A2 mediate the ability of Salmonella enterica serotype typhimurium and Shigella flexneri to induce the transepithelial migration of neutrophils.

Authors:  Karen L Mumy; Jeffrey D Bien; Michael A Pazos; Karsten Gronert; Bryan P Hurley; Beth A McCormick
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.